Oral therapies targeting the integrin α4β7 may offer unique advantages for treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models, and established safety, pharmacokinetic/pharmacodynamic relationships and efficacy in a phase 2a trial in ulcerative colitis (UC) patients.